Onyx Healthcare Valuation
Is 6569 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6569 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6569 (NT$150) is trading above our estimate of fair value (NT$26.31)
Significantly Below Fair Value: 6569 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6569?
Key metric: As 6569 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 6569's PE Ratio? | |
|---|---|
| PE Ratio | 31.7x |
| Earnings | NT$182.44m |
| Market Cap | NT$5.78b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 42.1x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 6569's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 36.2x | ||
4163 INTAI Technology | 28x | n/a | NT$5.8b |
1788 Hi-Clearance | 16.7x | n/a | NT$6.2b |
4126 Pacific Hospital Supply | 15.7x | 5.6% | NT$6.5b |
1784 BIONET | 84.3x | n/a | NT$4.7b |
6569 Onyx Healthcare | 31.7x | n/a | NT$5.8b |
Price-To-Earnings vs Peers: 6569 is good value based on its Price-To-Earnings Ratio (31.7x) compared to the peer average (36.2x).
Price to Earnings Ratio vs Industry
How does 6569's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 6569 is expensive based on its Price-To-Earnings Ratio (31.7x) compared to the Asian Healthcare Services industry average (23.9x).
Price to Earnings Ratio vs Fair Ratio
What is 6569's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6569's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Universal Vision Biotechnology
NT$18.3b
Operates a chain of eye care clinics in Taiwan and China.
3218
NT$215.50
7D
1.9%
1Y
-27.1%
Hi-Clearance
NT$6.2b
Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.
1788
NT$138.50
7D
0.4%
1Y
2.6%
Pacific Hospital Supply
NT$6.5b
Manufactures, processes, and sells medical disposable products and equipment in Taiwan.
4126
NT$89.00
7D
-0.3%
1Y
6.0%